| Literature DB >> 28555113 |
Chao Wang1,2, Michelle E Costanzo2,3, Paul E Rapp1, David Darmon1,2, Kylee Bashirelahi1,2, Dominic E Nathan1,2,4, Christopher J Cellucci5, Michael J Roy3, David O Keyser1.
Abstract
The objective of this research project is the identification of a physiological prodrome of post-traumatic stress disorder (PTSD) that has a reliability that could justify preemptive treatment in the sub-syndromal state. Because abnormalities in event-related potentials (ERPs) have been observed in fully expressed PTSD, the possible utility of abnormal ERPs in predicting delayed-onset PTSD was investigated. ERPs were recorded from military service members recently returned from Iraq or Afghanistan who did not meet PTSD diagnostic criteria at the time of ERP acquisition. Participants (n = 65) were followed for up to 1 year, and 7.7% of the cohorts (n = 5) were PTSD-positive at follow-up. The initial analysis of the receiver operating characteristic (ROC) curve constructed using ERP metrics was encouraging. The average amplitude to target stimuli gave an area under the ROC curve of greater than 0.8. Classification based on the Youden index, which is determined from the ROC, gave positive results. Using average target amplitude at electrode Cz yielded Sensitivity = 0.80 and Specificity = 0.87. A more systematic statistical analysis of the ERP data indicated that the ROC results may simply represent a fortuitous consequence of small sample size. Predicted error rates based on the distribution of target ERP amplitudes approached those of random classification. A leave-one-out cross validation using a Gaussian likelihood classifier with Bayesian priors gave lower values of sensitivity and specificity. In contrast with the ROC results, the leave-one-out classification at Cz gave Sensitivity = 0.65 and Specificity = 0.60. A bootstrap calculation, again using the Gaussian likelihood classifier at Cz, gave Sensitivity = 0.59 and Specificity = 0.68. Two provisional conclusions can be offered. First, the results can only be considered preliminary due to the small sample size, and a much larger study will be required to assess definitively the utility of ERP prodromes of PTSD. Second, it may be necessary to combine ERPs with other biomarkers in a multivariate metric to produce a prodrome that can justify preemptive treatment.Entities:
Keywords: P300; delayed onset; event-related potentials; post-traumatic stress disorder; prodromes; traumatic brain injury
Year: 2017 PMID: 28555113 PMCID: PMC5430065 DOI: 10.3389/fpsyt.2017.00071
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Studies reporting ERP abnormalities in PTSD-positive participants.
| Study | Reported observation(s) |
|---|---|
| Araki et al. ( | Lower amplitude ERPs at Pz in an auditory oddball task |
| Blomhoff et al. ( | Amplitudes to emotionally related words were significantly related to CAPS scores |
| Charles et al. ( | P300 amplitude lower in PTSD-positive participants |
| Felmingham et al. ( | Auditory oddball, PTSD positive participants show the following |
| Target stimuli: reduced P200 amplitude, reduced P300 amplitude, increased N200 amplitude, increased N200 latency, increased P300 latency | |
| Standard stimuli: reduced P200 amplitude | |
| Ghisolfi et al. ( | PTSD positive participants showed auditory P50 sensory gating deficits |
| Hansenne ( | Literature review includes PTSD |
| Javanbakht et al. ( | Literature review of 36 studies. Increased P300 response to trauma-related stimuli. P50 studies suggest impaired gating |
| Johnson et al. ( | P300a, P300b amplitudes larger with trauma related stimuli |
| P300b small with neutral stimuli | |
| P300 working memory amplitudes smaller | |
| Karl et al. ( | Reduced P50 suppression |
| Increase P300 amplitude to trauma-related stimuli | |
| Kimble et al. ( | Significant P300 amplitude enhancements to distracting stimuli |
| Kimble et al. ( | Larger frontal, smaller central, and parietal CNVs |
| McFarlane et al. ( | Delayed N200 P300 elicited by target and distracter tones indistinguishable |
| Metzger et al. ( | Parietal P300 amplitude to target tones were smaller in unmedicated PTSD positive participants |
| Metzger et al. ( | Modified Stroop task for personal traumatic, personal positive, and neutral words. PTSD-positive participants have reduced and delayed P300 across word type |
| Metzger et al. ( | Contrary to previous results, the PTSD group had larger P300b amplitude and increased P200 amplitude/intensity slopes |
| Neylan et al. ( | Impaired P50 gating to non-startle trauma-neutral auditory stimuli |
| Neylan et al. ( | Nine of 24 P300 measures were significantly less predictable over time in the PTSD-positive group |
| Shu et al. ( | mTBI only compared against mTBI + PTSD, larger emotional face processing ERPs in mTBI + PTSD |
| Shu et al. ( | mTBI only compared against mTBI + PTSD, larger inhibitory processing ERPs in mTBI + PTSD |
| Shucard et al. ( | PTSD group has longer P300 latency to NoGo stimuli and greater P300 amplitude to irrelevant non-target stimuli |
CAPS, Clinician-Administered PTSD Scale; CNV, contingent negative variation; ERP, event-related potential.
Subject characteristics and baseline psychological measures.
| Variable | Converter ( | Stable ( | Group comparison | ||||
|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | df | |||
| Age | 35.6 | 6.2 | 30.5 | 8.0 | 63 | 1.37 | 0.18 |
| Gender, male/female | 4/1 | 54/6 | 0.36 | ||||
| Handedness, R/L | 5/0 | 55/5 | 0.66 | ||||
| History of mTBI < 10 years, yes/no | 2/3 | 18/42 | 0.33 | ||||
| Clinician-Administered PTSD Scale total | 30.6 | 15.4 | 18.7 | 12.5 | 63 | 2.02 | 0.047 |
| Patient Health Questionnaire-9 score | 5.2 | 2.3 | 2.5 | 2.3 | 62 | 2.51 | 0.015 |
| PTSD Checklist-Military Version (PCL-M) score | 33.4 | 11.0 | 25.9 | 7.4 | 63 | 2.10 | 0.040 |
.
Figure 1P300 waveforms in converters and stables. Grand average ERPs in response to target and standard stimuli at the six electrodes. Blue lines represent waveforms for Stables. Red lines represent waveforms for Converters.
Baseline results from participants who remained PTSD-negative for one year after enrollment (.
| Baseline scores individuals | Baseline scores individuals | Between-group separation | ||
|---|---|---|---|---|
| PTSD-negative at 1 year stables | PTSD-positive at 1 year converters | Equal priors | ||
| Average Fz amplitude response to target stimulus (μV) | 9.87 ± 4.25 | 5.98 ± 2.38 | 0.0157 | 0.3193 |
| Average Cz amplitude response to target stimulus (μV) | 15.48 ± 5.45 | 9.71 ± 2.65 | 0.0038 | 0.2937 |
| Average Pz amplitude response to target stimulus (μV) | 16.18 ± 5.27 | 11.13 ± 3.71 | 0.0338 | 0.3130 |
| Average C3 amplitude response to target stimulus (μV) | 14.52 ± 5.16 | 9.34 ± 2.54 | 0.0054 | 0.3032 |
| Average C4 amplitude response to target stimulus (μV) | 14.72 ± 5.23 | 9.07 ± 2.67 | 0.0046 | 0.2898 |
| Average Fz latency response to target stimulus (ms) | 356.2 ± 43.8 | 357.0 ± 57.2 | 0.9760 | 0.4963 |
| Average Cz latency response to target stimulus (ms) | 359.7 ± 39.0 | 357.3 ± 57.6 | 0.9235 | 0.4868 |
| Average Pz latency response to target stimulus (ms) | 360.5 ± 42.4 | 374.2 ± 58.6 | 0.6345 | 0.4377 |
| Average C3 latency response to target stimulus (ms) | 359.4 ± 37.3 | 352.3 ± 68.2 | 0.8291 | 0.4646 |
| Average C4 latency response to target stimulus (ms) | 355.2 ± 36.9 | 355.5 ± 60.3 | 0.9928 | 0.4987 |
Area under the receiver operating curve and measures of diagnostic efficacy computed using the smallest value of threshold giving the maximum value of the Youden index.
| Measure | Average Fz amplitude response to target stimulus | Average Cz amplitude response to target stimulus | Average Pz amplitude response to target stimulus | Average C3 amplitude response to target stimulus | Average C4 amplitude response to target stimulus |
|---|---|---|---|---|---|
| Area under the curve | 0.7864 [0.5616, 0.8960] | 0.8533 [0.6708, 0.9347] | 0.7833 [0.4737, 0.9108] | 0.8233 [0.6170, 0.9185] | 0.8433 [0.5980, 0.9390] |
| Max Youden Index | 0.5763 | 0.6667 | 0.5500 | 0.6000 | 0.7000 |
| 9.0140 | 10.4186 | 12.1866 | 12.4016 | 9.1688 | |
| Diagnostic accuracy | 0.6094 | 0.8615 | 0.7538 | 0.6308 | 0.8923 |
| Sensitivity | 1.0000 | 0.8000 | 0.8000 | 1.0000 | 0.8000 |
| Specificity | 0.5763 | 0.8667 | 0.7500 | 0.6000 | 0.9000 |
| Positive likelihood ratio | 2.3600 | 6.0000 | 3.2000 | 2.5000 | 8.0000 |
| Negative likelihood ratio | 0.0000 | 0.2308 | 0.2667 | 0.0000 | 0.2222 |
| Diagnostic odds ratio | Undefined | 26.0000 | 12.0000 | Undefined | 36.0000 |
Figure 2The receiver operating characteristic (ROC) curve of the P300 amplitude at Cz. Horizontal axis is the false positive rate (1-specificity) which equals the number of false positive divided by the sum of false positive and true negative. Vertical axis is the true positive rate (sensitivity) which equals the number of true positives divided by the sum of true positive and false negative. The solid line represents the ROC curve for using the P300 amplitude at Cz as the diagnostic test. The dashed line represents the ROC curve for a random test.
Classification based on average target amplitudes determined by a leave-one-out calculation.
| Measure | Average Fz amplitude response to target stimulus | Average Cz amplitude response to target stimulus | Average Pz amplitude response to target stimulus | Average C3 amplitude response to target stimulus | Average C4 amplitude response to target stimulus |
|---|---|---|---|---|---|
| Number of true positives | 4 | 3 | 4 | 3 | 4 |
| Number of false positives | 25 | 21 | 25 | 24 | 23 |
| Number of false negatives | 1 | 2 | 1 | 2 | 1 |
| Number of true negatives | 34 | 39 | 35 | 36 | 37 |
| Diagnostic accuracy | 0.5938 | 0.6462 | 0.6000 | 0.6000 | 0.6308 |
| Sensitivity | 0.8000 | 0.6000 | 0.8000 | 0.6000 | 0.8000 |
| Specificity | 0.5763 | 0.6500 | 0.5833 | 0.6000 | 0.6167 |
| Number of true positives | 0 | 1 | 0 | 1 | 3 |
| Number of false positives | 6 | 7 | 3 | 7 | 8 |
| Number of false negatives | 5 | 4 | 5 | 4 | 2 |
| Number of true negatives | 53 | 53 | 57 | 53 | 52 |
| Diagnostic accuracy | 0.8281 | 0.8308 | 0.8769 | 0.8308 | 0.8462 |
| Sensitivity | 0.0000 | 0.2000 | 0.0000 | 0.2000 | 0.6000 |
| Specificity | 0.8983 | 0.8833 | 0.9500 | 0.8833 | 0.8667 |
Classification based on average target amplitudes determined by a bootstrap calculation.
| Measure | Average Fz amplitude response to target stimulus | Average Cz amplitude response to target stimulus | Average Pz amplitude response to target stimulus | Average C3 amplitude response to target stimulus | Average C4 amplitude response to target stimulus |
|---|---|---|---|---|---|
| Diagnostic accuracy | 0.6288 [0.4348, 0.8261] | 0.6719 [0.4500, 0.8621] | 0.6087 [0.3333, 0.8462] | 0.6431 [0.4500, 0.8261] | 0.6954 [0.4286, 0.9091] |
| Sensitivity | 0.6236 [0.0000, 1.0000] | 0.5916 [0.0000, 1.0000] | 0.6835 [0.0000, 1.0000] | 0.5790 [0.0000, 1.0000] | 0.6746 [0.0000, 1.0000] |
| Specificity | 0.6325 [0.4118, 0.9048] | 0.6802 [0.4211, 0.9444] | 0.6068 [0.3158, 0.9444] | 0.6513 [0.4211, 0.8846] | 0.6996 [0.3913, 1.0000] |
| Positive likelihood ratio | 1.6108 [0.4423, 3.2051] | 1.8999 [0.5882, 4.6667] | 1.6975 [0.3333, 3.8182] | 1.5957 [0.4058, 3.3409] | 2.6276 [0.7667, 7.0000] |
| Negative likelihood ratio | 0.6720 [0.2174, 1.3889] | 0.6592 [0.2121, 1.2857] | 0.6695 [0.2069, 1.8254] | 0.6992 [0.2114, 1.4457] | 0.5572 [0.2100, 1.1613] |
| Diagnostic odds ratio | 3.7930 [0.3176, 11.9231] | 4.3037 [0.4667, 15.6154] | 4.0970 [0.2000, 13.8889] | 3.9384 [0.2870, 13.8889] | 5.9901 [0.6863, 19.8000] |
| Diagnostic accuracy | 0.8282 [0.6364, 0.9583] | 0.8159 [0.6400, 0.9545] | 0.8647 [0.6818, 0.9615] | 0.8023 [0.6190, 0.9565] | 0.8562 [0.7143, 0.9583] |
| Sensitivity | 0.1533 [0.0000, 1.0000] | 0.3104 [0.0000, 1.0000] | 0.1481 [0.0000, 1.0000] | 0.2175 [0.0000, 1.0000] | 0.3513 [0.0000, 1.0000] |
| Specificity | 0.8887 [0.6667, 1.0000] | 0.8622 [0.6667, 1.0000] | 0.9269 [0.7200, 1.0000] | 0.8542 [0.6522, 1.0000] | 0.9030 [0.7273, 1.0000] |
| Positive likelihood ratio | 4.0682 [0.5778, 12.5000] | 3.3854 [0.6786, 12.0000] | 5.5863 [0.7407, 15.7500] | 3.0264 [0.4902, 12.0000] | 4.9856 [0.9286, 16.5000] |
| Negative likelihood ratio | 0.8286 [0.2949, 1.1667] | 0.7378 [0.2660, 1.1111] | 0.7963 [0.2805, 1.0811] | 0.8170 [0.2838, 1.2069] | 0.6722 [0.2000, 1.0135] |
| Diagnostic odds ratio | 6.1093 [0.4921, 19.8000] | 6.6509 [0.6104, 29.4000] | 8.6072 [0.6863, 39.0000] | 5.1757 [0.4026, 23.4000] | 10.2212 [0.9184, 43.0000] |
| Disease present | Disease absent | |
|---|---|---|
| Test positive | True positive | False positive |
| Test negative | False negative | True negative |